Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1

• Published in: Malaria Journal
• Main Authors: Looareesuwan Sornchai, Letourneur Frank, Rénia Laurent, Grüner Anne, Pukrittayakamee Sasithon, Imwong Mallika, White Nicholas J, Snounou Georges
• Format: Article in Journal/Newspaper
• Language: English
• Published: BMC 2005
• Subjects: Arctic medicine. Tropical medicine; RC955-962; Infectious and parasitic diseases; RC109-216; Arctic
• Online Access: https://doi.org/10.1186/1475-2875-4-20; https://doaj.org/article/afe3367bfc0f418c8d1642608c2a2f39

Abstract Background Plasmodium vivax is the second most prevalent malaria parasite affecting more than 75 million people each year, mostly in South America and Asia. In addition to major morbidity this parasite is associated with relapses and a reduction in birthweight. The emergence and spread of drug resistance in Plasmodium falciparum is a major factor in the resurgence of this parasite. P. vivax resistance to drugs has more recently emerged and monitoring the situation would be helped, as for P. falciparum , by molecular methods that can be used to characterize parasites in field studies and drug efficacy trials. Methods Practical PCR genotyping protocols based on polymorphic loci present in two P. vivax genetic markers, Pvcs and Pvmsp1 , were developed. The methodology was evaluated using 100 P. vivax isolates collected in Thailand. Results and Discussion Analysis revealed that P. vivax populations in Thailand are highly diverse genetically, with mixed genotype infections found in 26 % of the samples (average multiplicity of infection = 1.29). A large number of distinguishable alleles were found for the two markers, 23 for Pvcs and 36 for Pvmsp1 . These were generally randomly distributed amongst the isolates. A total of 68 distinct genotypes could be enumerated in the 74 isolates with a multiplicity of infection of 1. Conclusion These results indicate that the genotyping protocols presented can be useful in the assessment of in vivo drug efficacy clinical trials conducted in endemic areas and for epidemiological studies of P. vivax infections.